

1 **Emergence of the SARS-CoV-2 B.1.1.7 lineage and its characteristics at an outpatient**
2 **testing site in Berlin, Germany, January-March 2021**

3
4 Welmoed van Loon¹, Heike Rössig², Susen Burock³, Jörg Hofmann⁴, Julian Bernhardt¹,
5 Elizabeth Linzbach¹, Domenika Pettenkofer¹, Christian Schönfeld¹, Maximilian Gertler¹,
6 Joachim Seybold², Tobias Kurth⁵, Frank P. Mockenhaupt¹

7
8 1 Institute of Tropical Medicine and International Health, Charité - Universitätsmedizin
9 Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin,
10 Berlin, Germany

11 2 Medical Directorate, Charité - Universitätsmedizin Berlin, corporate member of Freie
12 Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany

13 3 Charité Comprehensive Cancer Center, Charité - Universitätsmedizin Berlin, corporate
14 member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany

15 4 Labor Berlin - Charité Vivantes GmbH, Berlin, Germany

16 5 Institute of Public Health, Charité-Universitätsmedizin Berlin, corporate member of Freie
17 Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany

18

19 **Corresponding author:** Welmoed van Loon, welmoed.van-loon@charite.de

20

21 **Abstract**

22 Within five weeks in early 2021, B.1.1.7 became the dominant SARS-CoV-2 lineage at an
23 outpatient testing site in Berlin. Characteristics including Ct-values of 193 and 125 recently ill
24 outpatients with B.1.1.7 and wildtype virus, respectively, were similar, except for more
25 commonly reported sore throat and travel, and less frequently stated loss of smell and taste in
26 the former.

27 The SARS-CoV-2 B.1.1.7 lineage (variant of concern [VOC] 202012/01, or 20I/501Y.V1)
28 likely emerged during autumn 2020 in the United Kingdom and quickly became the dominant
29 strain (1). It carries multiple mutations and deletions, including 501Y and deletion
30 Δ H69/ Δ V70 (del69–70) in the spike protein. The B.1.1.7 variant is considered to exhibit
31 increased transmissibility compared to non-VOC lineages (1), hereafter referred to as
32 wildtype virus, whereas increased fatality is ambiguous (2,3).

33 At the outpatient SARS-CoV-2 testing site of Charité - Universitätsmedizin Berlin, the
34 first patient infected with the B.1.1.7 variant was identified on January 18, 2021. Herein, we
35 describe lineage prevalence over time as well as demographic and clinical characteristics in
36 outpatients with the B.1.1.7 variant and those with the wildtype virus presenting until end of
37 March. Ethical approval for the analysis was obtained from Charité's institutional review
38 board (EA4/083/20).

39

40 **The study**

41 Details of the testing site have been described (4). Upon presentation, physicians interviewed
42 patients on demographics, medical history, and symptoms. If indicated, an combined oro-
43 nasopharyngeal swab was collected. SARS-CoV-2 infection was assessed applying a cobas®
44 6800/8800 analyzer (Roche Diagnostics, Mannheim, Germany), targeting both *ORF1ab* and *E*
45 *Gene* (5). All positive samples were typed for the N501Y and del69–70 polymorphisms by
46 melting curve analysis. Variants including both polymorphisms were considered B.1.1.7.

47 Between January 18 and March 29, 2021, 349 SARS-CoV-2 positive patients
48 presented. In this period, the proportion of the B.1.1.7 variant increased from 2% to >90%
49 (Figure 1). In total, 35.8% (125/349) of the samples belonged to the wildtype lineage, 57.0%
50 (199/349) were the B.1.1.7 variant, and 7.2% (25/349) other non-wildtype variants (non-
51 VOCs).

52 Six patients previously had received ≥ 1 SARS-CoV-2 vaccination (five, first dose
53 AZD1222 [Oxford-AstraZeneca] 4-24 days before; one, second BNT162b2
54 [Pfizer/BioNTech] dose 66 days before); all were infected with B.1.1.7 and were excluded
55 from analysis as were patients carrying lineages other than wildtype or B.1.1.7. Half of the
56 patients were female (49%); mean age was 36 ± 15 years. Almost all reported symptoms
57 (97%). Median symptom duration until testing was 3 days (IQR, 2, 4). Leading complaints
58 were fatigue (72%), headache (69%), and muscle ache (60%). Fifteen percent reported travel

59 outside of Berlin in the last fourteen days, and half (49%) had had contact with a confirmed
60 SARS-CoV-2 case (Table 1).

61 Most assessed characteristics did not substantially differ between patients carrying the
62 SARS-CoV-2 wildtype or the B.1.1.7 lineage, including age, sex, leading complaints,
63 symptom duration, contacts to a confirmed case, and time passed since such contacts (Table
64 1). However, B.1.1.7 patients had travelled more frequently than those infected with the
65 wildtype strain (19% vs. 10%). As for symptoms, patients with B.1.1.7 more often reported
66 sore throat than those with the wildtype lineage (54% vs. 42%) but less often loss of
67 smell/taste (24% vs. 38%) (Table 1).

68 We observed no difference in cycle threshold (Ct)-values for the *E Gene* target
69 between B.1.1.7 and wildtype samples (medians, 20.2 vs. 20.1) (Table 1). In patients reporting
70 a symptom duration of ≥ 7 days, Ct-values appeared to be lower for the B.1.1.7 lineage
71 (median, 26.2; wildtype, 30.1; Mann-Whitney-U-test, $P=0.7$) (Table 1, Figure 2).

72 Lastly, we explored which combination of variables in our dataset best predicted the
73 B.1.1.7 variant in a logistic regression applying a backward stepwise selection based on the
74 Akaike information criterion. This identified the best set of predictors as absent loss of
75 smell/taste ($P=0.01$), longer symptom duration ($P=0.02$), sore throat ($P=0.05$), lower Ct-
76 value ($P=0.07$), travel in the last 14 days ($P=0.08$), lower age ($P=0.09$), and absent
77 rhinorrhea ($P=0.12$). We then used bootstrap technique to repeat the variable selection in
78 1,000 replicated datasets and evaluated how often these variables were selected with the
79 backward selection. This resulted in loss of smell/taste, 89%; symptom duration, 78%; travel,
80 73%; sore throat, 68%; Ct-value, 66%; age, 56%; rhinorrhea, 51%. Absent loss of smell/taste,
81 longer symptom duration, and travel were selected most often, indicating their importance in
82 B.1.1.7 variant prediction. All analyses were done in R version 3.6.3.

83

84 **Discussion**

85 The first B.1.1.7 case in Germany was notified in late December 2020 (6). At our testing site,
86 the B.1.1.7 lineage was first observed three weeks later and replaced the wildtype virus as the
87 dominant strain within five weeks only. The rapid emergence and dominance of this lineage
88 likely results from its increased transmissibility (1), which is potentially caused by spike
89 protein polymorphisms including 501Y conferring enhanced mucosal binding (7); 681H, near
90 a region important for transmission (8); deletion 69-70, linked to immune escape (9). Viral
91 replication *in vitro* does not differ from pre-existing strains (10).

92 The B.1.1.7 variant reportedly is associated with increased mortality (2), although this
93 has been questioned (3). In our young outpatient study population, we did not observe major,
94 lineage-dependent differences in leading symptoms. Nevertheless, loss of smell/taste, among
95 the most specific COVID-19 symptoms (4), was less common in patients infected with
96 B.1.1.7., whereas, sore throat was more frequently reported than in wildtype virus patients.
97 Similarly, a UK survey revealed less loss of smell/taste in B.1.1.7 patients but more sore
98 throat, cough, fatigue, myalgia, and fever (11). In contrast, no associations between SARS-
99 CoV-2 B.1.1.7 and self-reported symptoms, disease duration, or hospital admissions were
100 seen in another UK study (12). The most important factors for B.1.1.7 infection prediction in
101 our study appeared to be loss of smell/taste and longer symptom duration, in addition to
102 recent travel.

103 As for Ct-values, one study observed similar figures in patients infected with B.1.1.7
104 and wildtype lineages; however, a longer duration of infection with the B.1.1.7 variant was
105 suggestive by repeated sampling over time (13). Likewise, longer persistence has been
106 observed for B.1.1.7 (14), but also lower Ct-values (higher viral load) compared to wildtype
107 samples. Lower Ct-values were also seen in other studies on population (15) and inpatient
108 levels (3). In our cross-sectional assessment of recently ill outpatients, we did not observe
109 such differences. Still, increased transmissibility may result from the variant's prolonged
110 excretion (13,14). Test timing appears crucial for the interpretation of Ct-values. Outpatients
111 are commonly tested earlier in the course of infection than inpatients. The combination of
112 prolonged viral shedding with different test timing might explain increased viral load in
113 B.1.1.7 samples in inpatients, but not in recently ill outpatients. In support of that, in our
114 outpatients with ≥ 7 days symptom duration, Ct-values in B.1.1.7 samples were suggestively
115 reduced. However, the comparison groups were small. Our data enable to detect a maximum
116 effect size on overall Ct-values, which corresponds to B.1.1.7 Ct-values being 1.5 units below
117 wildtype, or 1.0 above.

118 The main limitation in our study are limited subgroup sizes, which reduced the
119 likelihood to detect differences between rare characteristics. Others are the one-time
120 assessment, subjective symptom duration, and the variable manifestation of SARS-CoV-2
121 infection (4). Strengths include standardized procedures conducted by trained medical staff
122 and the prospective nature of the study evaluating patient groups during the same time period,
123 reducing the likelihood of confounding due to temporal effects.

124 SARS-CoV-2 VOC B.1.1.7 is now the dominant lineage in Berlin. On the outpatient
125 level, there appears to be no major difference in clinical manifestation.

126

127 **Acknowledgments**

128 We thank the Corona Untersuchungsstelle (CUS) staff at the Charité - Universitaetsmedizin
129 Berlin for their dedication and hard work during the COVID-19 pandemic.

130

131 **References**

- 132 1. Volz E, Mishra S, Chand M, Barrett JC, Johnson R, Hopkins S, et al.
133 Transmission of SARS-CoV-2 Lineage B.1.1.7 in England: Insights from
134 linking epidemiological and genetic data. *MedRxiv [Preprint]*. 2021 [cited 2021
135 Apr 1]. Available from:
136 <https://www.medrxiv.org/content/10.1101/2020.12.30.20249034v2>.
- 137 2. Davies NG, Jarvis CI, CMMID COVID-19 Working Group, Edmunds WJ,
138 Jewell NP, Diaz-Ordaz K, et al. Increased mortality in community-tested cases
139 of SARS-CoV-2 lineage B.1.1.7. *Nature*. 2021 Mar 15;1–5. doi:
140 [10.1038/s41586-021-03426-1](https://doi.org/10.1038/s41586-021-03426-1).
- 141 3. Frampton D, Rampling T, Cross A, Bailey H, Heaney J, Byott M, et al. Genomic
142 characteristics and clinical effect of the emergent SARS-CoV-2 B.1.1.7 lineage
143 in London, UK: a whole-genome sequencing and hospital-based cohort study.
144 *Lancet Infect Dis*. 2021 Apr 12;0(0). doi: [10.1016/S1473-3099\(21\)00170-5](https://doi.org/10.1016/S1473-3099(21)00170-5).
- 145 4. Maechler F, Gertler M, Hermes J, van Loon W, Schwab F, Piening B, et al.
146 Epidemiological and clinical characteristics of SARS-CoV-2 infections at a
147 testing site in Berlin, Germany, March and April 2020—a cross-sectional study.
148 *Clin Microbiol Infect*. 2020 Dec;26(12):1685.e7-1685.e12. doi:
149 [10.1016/j.cmi.2020.08.017](https://doi.org/10.1016/j.cmi.2020.08.017).
- 150 5. Poljak M, Korva M, Gašper NK, Komloš KF, Sagadin M, Uršič T, et al. Clinical
151 evaluation of the cobas SARS-CoV-2 test and a diagnostic platform switch
152 during 48 hours in the midst of the COVID-19 pandemic. *J Clin Microbiol*. 2020
153 May 26;58(6):e00599-20. doi: [10.1128/JCM.00599-20](https://doi.org/10.1128/JCM.00599-20).
- 154 6. Robert Koch Institute. Coronavirus Disease 2019 (COVID-19) Daily Situation
155 Report of the Robert Koch Institute. 26/12/2020. 2020. Available from:
156 [https://www.rki.de/DE/Content/InfAZ/N/Neuartiges_Coronavirus/Situationsber
157 chte/Dez_2020/2020-12-26-en.pdf?__blob=publicationFile](https://www.rki.de/DE/Content/InfAZ/N/Neuartiges_Coronavirus/Situationsberichte/Dez_2020/2020-12-26-en.pdf?__blob=publicationFile)
- 158 7. Chan KK, Tan TJC, Narayanan KK, Procko E. An engineered decoy receptor for
159 SARS-CoV-2 broadly binds protein S sequence variants. *Sci Adv*. 2021 Feb
160 17;7(8):eabf1738. doi: [10.1126/sciadv.abf1738](https://doi.org/10.1126/sciadv.abf1738).
- 161 8. Peacock TP, Goldhill DH, Zhou J, Baillon L, Frise R, Swann OC, et al. The
162 furin cleavage site of SARS-CoV-2 spike protein is a key determinant for
163 transmission due to enhanced replication in airway cells. *BioRxiv [Preprint]*;

- 164 2020 [cited 2021 Apr 14]. Available from:
165 <https://doi.org/10.1101/2020.09.30.318311>.
- 166 9. Kemp SA, Collier DA, Datir R, Ferreira IATM, Gayed S, Jahun A, et al.
167 Neutralising antibodies in Spike mediated SARS-CoV-2 adaptation. *Nature*.
168 2021 Apr;592(7853):277-282. doi: 10.1038/s41586-021-03291-y.
- 169 10. Brown JC, Goldhill DH, Zhou J, Peacock TP, Frise R, Goonawardane N, et al.
170 Increased transmission of SARS-CoV-2 lineage B.1.1.7 (VOC 2020212/01) is
171 not accounted for by a replicative advantage in primary airway cells or antibody
172 escape. *BioRxiv [Preprint]*. 2021 [cited 2021 Apr 3]; Available from:
173 <https://doi.org/10.1101/2021.02.24.432576>.
- 174 11. Office for National Statistics. Coronavirus (COVID-19) Infection Survey:
175 characteristics of people testing positive for COVID-19 in England. 2021.
176 Available from:
177 [https://www.ons.gov.uk/peoplepopulationandcommunity/healthandsocialcare/co](https://www.ons.gov.uk/peoplepopulationandcommunity/healthandsocialcare/conditionsanddiseases/articles/coronaviruscovid19infectionsinthecommunityinengland/characteristicsofpeopletestingpositiveforcovid19inengland27january2021)
178 [nditionsanddiseases/articles/coronaviruscovid19infectionsinthecommunityinengl](https://www.ons.gov.uk/peoplepopulationandcommunity/healthandsocialcare/conditionsanddiseases/articles/coronaviruscovid19infectionsinthecommunityinengland/characteristicsofpeopletestingpositiveforcovid19inengland27january2021)
179 [and/characteristicsofpeopletestingpositiveforcovid19inengland27january2021](https://www.ons.gov.uk/peoplepopulationandcommunity/healthandsocialcare/conditionsanddiseases/articles/coronaviruscovid19infectionsinthecommunityinengland/characteristicsofpeopletestingpositiveforcovid19inengland27january2021)
- 180 12. Graham MS, Sudre CH, May AM, Antonelli M, Murray B, Varsavsky T, et al.
181 Changes in symptomatology, re-infection and transmissibility associated with
182 SARS-CoV-2 variant B.1.1.7: an ecological study The COVID-19 Genomics
183 UK (COG-UK) consortium. *MedRxiv [Preprint]*. 2021 [cited 2021 Apr 1];
184 Available from:
185 <https://www.medrxiv.org/content/10.1101/2021.01.28.21250680v2>.
- 186 13. Kissler SM, Fauver JR, Mack C, Tai CG, Watkins AE, Samant RM, et al.
187 Densely sampled viral trajectories suggest longer duration of acute infection
188 with B.1.1.7 variant relative to non-B.1.1.7 SARS-CoV-2. *MedRxiv*
189 *[Preprint]*. 2021 [cited 2021 Mar 30]; Available from:
190 <https://doi.org/10.1101/2021.02.16.21251535>.
- 191 14. Calistri P, Amato L, Puglia I, Cito F, Di Giuseppe A, Danzetta ML, et al.
192 Infection sustained by lineage B.1.1.7 of SARS-CoV-2 is characterised by
193 longer persistence and higher viral RNA loads in nasopharyngeal swabs. *Int J*
194 *Infect Dis*. 2021 Mar 5;105:753-755. doi: 10.1016/j.ijid.2021.03.005.
- 195 15. Kidd M, Richter A, Best A, Cumley N, Mirza J, Percival B, et al. S-variant
196 SARS-CoV-2 lineage B1.1.7 is associated with significantly higher viral loads in

197 samples tested by ThermoFisher TaqPath RT-qPCR. J Infect Dis. 2021 Feb
198 13:jiab082. doi: 10.1093/infdis/jiab082.
199


200 **Table 1. Characteristics of SARS-CoV-2 positive outpatients attending the Charité**
 201 **testing site, separated by wildtype and B.1.1.7 lineages**

	Wildtype lineage N=125 (%, mean [SD], or median [25 th , 75 th quantile])	B.1.1.7 variant N=193 (%, mean [SD], or median [25 th , 75 th quantile])	OR [95%CI], difference in mean [95%CI], or difference in median [95%CI]*
Female	44.8%	51.0%	1.3 (0.8, 2.0)
Age, years	36.6 (13.8)	34.8 (15.9)	1.8 (-1.5, 5.1)
Any symptoms	97.6%	96.4%	0.7 (0.2, 2.6)
Self-reported fever in the last 48 hours	38.4%	42.5%	1.2 (0.8, 1.9)
Temperature in case of fever (°C, by patient statement)	38.3 (0.6)	38.2 (0.7)	0.1 (-0.2, 0.4)
Short of breath	9.6%	13.5%	1.5 (0.7, 3.0)
Fatigue	73.6%	71.5%	0.9 (0.5, 1.5)
Pain on the chest	2.4%	1.0%	0.4 (0.1, 2.6)
Diarrhea	15.2%	12.4%	0.8 (0.4, 1.5)
Loss of smell/taste	37.6%	23.8%	0.5 (0.3, 0.9)
Muscle ache	60.0%	60.1%	1.0 (0.6, 1.6)
Sore throat	41.6%	53.9%	1.6 (1.0, 2.6)
Cough	48.8%	50.8%	1.1 (0.7, 1.7)
Headache	68.8%	68.9%	1.0 (0.6, 1.6)
Chills	35.2%	34.7%	1.0 (0.6, 1.6)
Rhinorrhea	60.8%	52.8%	0.7 (0.5, 1.1)
Symptom duration upon test (days)	3.0 (2.0, 4.8)	3.0 (2.0, 4.0)	0.0 (-1.0, 0.0)
Contact to a confirmed SARS-CoV-2 case	48.0%	50.3%	1.1 (0.7, 1.7)
Time between contact to a confirmed SARS-CoV-2 case and test (days)	4.0 (1.2, 7.0)	4.0 (1.0, 6.0)	0.0 (-1.5, 3.0)
Traveled outside the	9.6%	18.7%	2.2 (1.1, 4.3)

	Wildtype lineage	B.1.1.7 variant	OR [95%CI], difference in mean [95%CI], or difference in median [95%CI]*
	N=125	N=193	
	(%, mean [SD], or median [25 th , 75 th quantile])	(%, mean [SD], or median [25 th , 75 th quantile])	
<hr/>			
Berlin region in the last 14 days			
Ct-value	20.2 (17.4, 24.1)	20.1 (17.1, 22.8)	0.1 (-0.9, 1.6)
Symptom duration < 7 days	N=113; 19.9 (17.4, 23.5)	N =171; 19.5 (16.6, 22.6)	0.4 (-1.0, 1.7)
Symptom duration ≥ 7 days	N=6; 30.1 (26.1, 31.3)	N=11; 26.2 (21.4, 31.2)	3.9 (-5.6, 10.0)

202 * The 95% confidence interval for the difference in medians was computed by a percentile
203 bootstrap with 1,000 replications.


204



205

206 **Figure 1. Proportion of SARS-CoV-2 lineages at the Charité testing site, 2021.** The
207 numbers on top of the bars indicate the total number of positive SARS-CoV-2-tests assessed.
208 Six (partially) vaccinated outpatients are included for completeness. Note that calendar week
209 13 only includes one day (March 29).

210



211

212 **Figure 2. Comparison of median Ct-values in SARS-CoV-2 wildtype and B.1.1.7 lineage,**
213 **by symptom duration.** The boxplots indicate medians, 25th and 75th percentiles (i.e., Q1 and
214 Q3). The upper whiskers reach the largest value with a maximum $Q3 + 1.5 * \text{interquartile}$
215 range (IQR) . The lower whiskers reach the smallest value with a minimum $Q1 - 1.5 * \text{IQR}$.
216 The numbers on top of the boxplots indicate the total number of observations included in the
217 comparison.